Shield Therapeutics plc
("Shield Therapeutics" or the "Company")
PDMR Transaction Notification
London, UK, 05 March 2021: Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that Hans Peter Hasler, Non-Executive Chairman, acquired 200,000 Ordinary Shares in the Company on 05 March 2021 at an average price of 0.375 pence per share. Following the transaction, Mr Hasler has a beneficial interest in 500,000 shares.
The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a. | Name | Hans Peter Hasler | ||||
| 2. | Reason for the notification | |||||
| a. | Position/status | Non-Executive Chairman | ||||
| b. | Initial notification /Amendment | Initial | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a. | Name | Shield Therapeutics plc | ||||
| b. | LEI | 213800G74QWY15FC3W71 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a. | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1.5p each in the capital of the Company
ISIN of Ordinary Shares: GB00BYV81293 | ||||
| b. | Nature of the transaction |
Acquisition of Ordinary Shares
| ||||
| c. | Price(s) and volume(s) |
| ||||
| d. | Aggregated information · Aggregated volume · Price
|
200,000
£75,000
| ||||
| e. | Date of the transaction | 2021-03-05 | ||||
| f. | Place of the transaction | London Stock Exchange, AIM Market
| ||||
For further information, please contact:
| Shield Therapeutics plc | +44 (0) 191 511 8500 | ||
| Tim Watts (CEO) | | ||
| | | ||
| Peel Hunt LLP - Nominated Adviser, Joint Broker and Bookrunner | +44 (0) 20 7148 8900 | ||
| James Steel / Dr Christopher Golden | | ||
| | | ||
| finnCap Ltd - Joint Broker and Bookrunner | +44 (0) 20 7220 0500 | ||
| Geoff Nash / Matthew Radley / Alice Lane | | ||
| | | ||
| Walbrook PR - Financial PR & IR Adviser | +44 (0) 20 7933 8780 | ||
| Paul McManus / Lianne Cawthorne | or shield@walbrookpr.com | ||
About Shield
Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol)®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see www.shieldtherapeutics.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
